Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces extracellular adenosine (eADO), which not only inhibits antitumor T cell activity via the adenosine receptor (AR) A2AR, but also enhances the...

Full description

Bibliographic Details
Main Authors: Zoya Kurago, Gang Guo, Huidong Shi, Roni J. Bollag, Michael W. Groves, J. Kenneth Byrd, Yan Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
CD73
NT5E
CD39
adenosine
A2AR
A2BR
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212209/full

Similar Items

Similar Items